Biomarker Study for ALS

(TALSLB Trial)

Recruiting at 14 trial locations

Overseen By Laura Dugom, MPH

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Target ALS Foundation, Inc.

Disqualifiers: Neurological disease, ALS genetic mutations

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 6

1000 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to help researchers study Amyotrophic Lateral Sclerosis (ALS) by collecting and storing samples such as blood and spinal fluid, along with clinical information, over time. Researchers will use these samples to identify patterns or clues that could lead to better treatments. Individuals with ALS who can visit a clinic every four months, as well as healthy individuals without neurological issues, are invited to participate. Participants will contribute to a valuable resource for future ALS research. As an unphased trial, this study offers participants the chance to contribute to groundbreaking research that could pave the way for new ALS treatments.

Do I need to stop my current medications to join the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

Why are researchers excited about this trial?

Researchers are excited about this trial because it explores innovative ways to track the progression of ALS, a condition that currently lacks a cure and has limited treatment options. Unlike existing treatments that primarily focus on managing symptoms, this study looks at gathering detailed data through longitudinal biofluids, clinical measures, and at-home assessments. These methods can provide a more comprehensive understanding of the disease's progression in real-time, potentially leading to earlier interventions and more personalized treatment plans. This approach could pave the way for breakthroughs in how ALS is diagnosed and monitored, offering hope for improved patient outcomes.

Who Is on the Research Team?

Laura Dugom, MPH

Principal Investigator

Target ALS Foundation, Inc.

Amy Easton, PhD

Principal Investigator

Target ALS Foundation, Inc.

Are You a Good Fit for This Trial?

Inclusion Criteria

I don't have any genetic mutations linked to ALS.

I am 18 years old or older.

My lung capacity is at least 30% of the expected value for my age, height, and gender.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Baseline

Initial collection of biofluids and clinical measures from participants

1 visit

1 visit (in-person)

Longitudinal Collection

Collection of biofluids, clinical measures, and at-home measures over time

5 years

5 visits (in-person) every 4 months for ALS participants; 2 visits (in-person) with 12-month interval for healthy controls

Follow-up

Participants are monitored for safety and effectiveness after the main collection period

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Longitudinal Biofluids, Clinical Measures, and At Home Measures

Who Is Running the Clinical Trial?

Target ALS Foundation, Inc.

Lead Sponsor

Trials

1

Recruited

1,000+